Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 1;31(6):261-269.
doi: 10.1097/MOH.0000000000000831. Epub 2024 Jul 15.

Donor selection in allogeneic stem cell transplantation

Francisco Barriga  1 , Alberto Cardoso Martins Lima  2
Affiliations
Review

Donor selection in allogeneic stem cell transplantation

Francisco Barriga et al. Curr Opin Hematol. .

Abstract

Purpose of review: Recent progress in human leukocyte antigen (HLA) characterization, increased accrual of unrelated donors and cord blood units, and a new platform for haploidentical transplantation have resulted in the widespread availability of donors for allogeneic hematopoietic stem cell transplantation.

Recent findings: Advances in HLA typing have identified an increasing number of loci and alleles that are crucial for successful transplantation. Newer HLA A, B, C, DRB1, and DQB1 alleles, DPB1 mismatches, and HLA B leader sequence matching are incorporated into donor selection algorithms. Donor selection is highly relevant because of recently published conflicting studies using different donor types. These studies are largely retrospective and compare patients with different diseases and stages, conditioning regimens, graft versus host disease (GVHD) prophylaxis, and time periods. A broad consensus indicates that the best donor is an available matched sibling, followed by a matched unrelated donor, and then alternative donors such as haploidentical, mismatched unrelated, and cord blood units. This consensus is being challenged by other factors, such as donor age, patient condition, urgency of transplantation, and costs involved.

Summary: In this review, we will analyze the unique characteristics of each donor type, the HLA and non HLA factors that affect donor choices, and the outstanding comparative outcome studies of different donor usage in hematologic malignancies.

PubMed Disclaimer

References

    1. Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of nonidentical family donors. Haematologica 2022; 107:1045–1053.
    1. Mohty M, Malard F. Increasing donor options in allogenic hematopoietic cell transplantation. J Clin Oncol 2021; 39:1951–1954.
    1. Bolon YT, Atshan R, Allbee-Johnson M, et al . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2022. Available at: http://www.cibmtr.org .
    1. Passweg JR, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT Activity Survey. Bone Marrow Transplant 2023; 58:647–658.
    1. Besse K, Maiers M, Confer D, Albrecht M. On modeling human leukocyte antigen–identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. Biol Blood Marrow Transplant 2016; 22:410–417.

MeSH terms